Pasithea Therapeutics
KTTA
26 hedge funds and large institutions have $16.7M invested in Pasithea Therapeutics in 2025 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 7 increasing their positions, 3 reducing their positions, and 5 closing their positions.
3,680% more capital invested
Capital invested by funds: $441K → $16.7M (+$16.2M)
140% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 5
133% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 3
49.48% more ownership
Funds ownership: 8.23% → 57.71% (+49%)
37% more funds holding
Funds holding: 19 → 26 (+7)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.85M |
| 2 |
Janus Henderson Group
London,
|
+$1.85M |
| 3 |
VC
Vivo Capital
Palo Alto,
California
|
+$1.85M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
+$1.7M |
| 5 |
CCC
Cable Car Capital
San Francisco,
California
|
+$439K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$22.5K |
| 2 |
VF
Virtu Financial
New York
|
-$18K |
| 3 |
TSS
Two Sigma Securities
New York
|
-$15.3K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$11.9K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$9.8K |
KTTA Hedge Fund Activity: Q4 2025 in Review
26 of the 8,281 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q4 2025, worth a combined $16.7M — up 3,680% from $441K a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new KTTA positions and 5 closed out — a net gain of 7 holders — while 7 added to existing stakes and 3 trimmed.
The largest buyer was Adage Capital Partners, opening a new position worth an estimated $1.85M. The largest seller was Renaissance Technologies, exiting entirely with an estimated $22.5K sold.
- 26 institutional investors held Pasithea Therapeutics (KTTA) as of Q4 2025, up from 19 in Q3 2025.
- Funds reported $16.7M of Pasithea Therapeutics stock for Q4 2025, up 3,680% quarter-over-quarter.
- 12 funds opened new Pasithea Therapeutics positions in Q4 2025 and 5 closed out, a net change of +7 holders.
- The largest Pasithea Therapeutics buyer in Q4 2025 was Adage Capital Partners, an estimated $1.85M added.
- The largest Pasithea Therapeutics seller in Q4 2025 was Renaissance Technologies, an estimated $22.5K sold.
Based on aggregated 13F filings for Q4 2025.